Styrene is pneumotoxic in mice. It is metabolized by pulmonary microsomes of both mouse and rat to styrene oxide (SO), presumed to be the toxic metabolite of styrene, and known to be genotoxic. To determine which pulmonary cell types are responsible for styrene metabolism, and which cytochromes P450 are associated with the bioactivation of styrene, we isolated enriched fractions of mouse and rat Clara and type II cells in order to determine the rate of styrene metabolism, with and without chemical inhibitors. Mouse Clara cells readily metabolized styrene to SO. Diethyldithiocarbamate, a CYP2E1 inhibitor, caused less inhibition of SO formation in Clara cells isolated from mice than previously found with pulmonary microsomes. As in microsomes, 5-phenyl-1-pentyne, a CYP2F2 inhibitor, inhibited the formation of both enantiomers. ␣-Naphthoflavone, a CYP1A inhibitor, did not inhibit SO formation in Clara cells. ␣-Methylbenzylaminobenzotriazole, a CYP2B inhibitor, exhibited minimal inhibition of SO production at 10 M and less at 1 M. The microsomal and isolated cell studies indicate that CYP2E1 and CYP2F2 are the primary cytochromes P450 involved in pulmonary styrene metabolism. Styrene metabolizing activity was much greater in Clara cells than in type II pneumocytes, which demonstrated essentially no activity. Styrene-metabolizing activity was several-fold higher in the mouse than in rat Clara cells. The more pneumotoxic and genotoxic form, R-SO, was preferentially formed in mice, and S-SO was preferentially formed in rats. These findings indicate the importance of Clara cells in styrene metabolism and suggest that differences in metabolism may be responsible for the greater susceptibility of the mouse to styrene-induced toxicity.
Human exposure to styrene occurs in a number of occupational settings, particularly in the reinforced plastics industry (Miller et al., 1994) . Styrene is both pneumotoxic and hepatotoxic in mice (Gadberry et al., 1996; Morgan et al., 1993a,b) . This is related to its bioactivation to enantiomeric styrene oxide, which is toxic to mice, with the (R) enantiomer being more acutely pneumotoxic than the (S) enantiomer (Gadberry et al., 1996) . The (R) enantiomer is preferentially formed in mice, especially in the lung (Carlson, 1997a) . In rats, which are less susceptible to styrene toxicity (Roycroft et al., 1992) , the (S) enantiomer is preferentially formed (Foureman et al., 1989; Watabe et al., 1981) . Pagano et al. (1982) and Sinsheimer et al. (1993) have shown that the (R) enantiomer of styrene oxide is more mutagenic in Salmonella.
The identification of which cytochromes P450 are responsible for the pulmonary metabolism of styrene is important in establishing species and target organ specificities. Studies on styrene metabolism in rat lung and liver implicate CYP2C11, CYP2B1, CYP1A1/2, and CYP2E1 (Nakajima et al., 1994a) . Studies with cDNA-expressed human forms of cytochromes P450 indicate CYP2B6 and CYP2F1 may also be involved (Nakajima et al., 1994b) . The distribution of specific cytochromes P450 in styrene metabolism is related to lung cell type. Xenobiotic metabolizing enzyme activity has been associated with type II and Clara cells with emphasis placed on their possible role in either pulmonary or systemic toxicity of chemicals (Cho et al., 1995; Dormans and VanBree, 1995; Nemery and Hoet, 1993) . CYP2B has been identified in both Clara and type II cells (Lacy et al., 1992; Lee and Dinsdale, 1995) with similar amounts reported in both cell types (Voigt et al., 1990) or in some cases higher amounts in Clara cells (Lag et al., 1993; Martin et al., 1993) . CYP1A has been identified in both cell types (Reitjiens et al., 1988) but is generally found to a greater extent in type II cells in rats (Voigt et al., 1990) . Chichester et al. (1991) reported that it is absent from mouse Clara cells. CYP1A is inducible in type II cells in rats (Lacy et al., 1992; Rabovsky et al., 1990) and in Clara cells (Lacy et al., 1992) .
The location of CYP2E1 is unclear since Lag et al. (1993) identified the apoprotein in both Clara and type II cells in rats, but Forkert (1995) using in situ hybridization and immunohistochemical methods to localize CYP2E1 concluded that it is preferentially expressed in Clara cells in mice. Interestingly, the Clara cell and the type II alveolar cell are the ones associated with lung tumors in A/J mice following the administration of ethyl carbamate (urethane), which is dependent upon CYP2E1 for bioactivation (Damak et al., 1996) . CYP2F1, which is expressed in human lung and CYP2F2, which is expressed in mouse lung and liver, are in the same gene subfamily (Nhamburo et al., 1990) .
In view of the potential contributions of multiple cyto-chromes P450 to styrene metabolism, effects of inhibitors of specific cytochrome P450 isozymes have been examined in mouse hepatic and pulmonary microsomal preparations (Carlson, 1997b; Carlson et al., 1998) . Diethyldithiocarbamate (DDTC), considered a relatively specific inhibitor of CYP2E1 (Ono et al., 1996) , inhibited the formation of both enantiomers of styrene oxide in lung and liver. 5-Phenyl-1-pentyne (5P1P), an inhibitor of CYP2F2 (Chang et al., 1996) , showed a high degree of inhibition in pulmonary microsomes, but caused only a small decrease in hepatic microsomes. SKF-525A, a nonspecific cytochrome P450 inhibitor (Ono et al., 1996) , effectively inhibited the formation of both enantiomers of styrene oxide in hepatic microsomes, and the S-enantiomer in pulmonary microsomes (Carlson 1997b ). ␣-Naphthoflavone, an inhibitor of CYP1A, had little effect on styrene metabolism (Carlson et al., 1998) . ␣-Methylbenzylaminobenzotriazole (MBA), which has been shown to be a potent and isozyme selective inhibitor of CYP2B (Mathews and Bend, 1986) caused only a 16 to 19% inhibition of styrene oxide formation at a concentration (1 M) which caused substantial (87%) inhibition of benzyloxyresorufin metabolism (Carlson et al., 1998) . The current study had several objectives. One was to identify the primary cell types involved in pulmonary styrene metabolism. A second goal was to determine contributions of specific cytochromes P450 involved in metabolism of styrene to styrene oxide by isolated cells. A third aim was to compare mice with rats in an attempt to identify metabolic differences that could account for the mouse being more susceptible to styrene induced toxicity. The final objective was to synthesize this information on cell and species differences, with respect to the rates of formation of styrene oxide enantiomers as dictated by the presence of the specific cytochromes P450 in these cells. If the cell types and cytochrome P450 isozymes involved in styrene metabolism could be identified, it would be valuable progress towards better understanding of potential risks associated with styrene exposure in humans. Clara cells isolation procedure. Two procedures were used for the isolation of enriched cell fractions. When only Clara cells were isolated, the procedure used was an adaptation of that of Malkinson et al. (1993) . Buffer A, used for perfusion, storage of lungs prior to digestion and to make the lavage solution, contained 133 mM NaCl, 5 mM KCl, 2.7 mM sodium phosphate buffer, 10 mM HEPES, 5.6 mM glucose, and gentamicin (0.10 g/ml of solution). The lavage solution was made by adding 3 ml 0.1 M EGTA to 146 ml Buffer A. Buffer B, used for making the digestion solution and rinsing during the filtering process, contained 129 mM NaCl, 5 mM KCl, 2.6 mM sodium phosphate buffer, 10 mM HEPES, 1.9 mM CaCl 2 , 1.3 mM MgSO 4 , 5.6 mM glucose, and gentamicin (0.10 g/ml solution). Kreb's/Ringer/HEPES (KRH) Buffer (pH 7.4), used for rinsing cells off the IgG plate and suspending the cells, contained 145 mM NaCl, 5.4 mM KCl, 1.4 mM CaCl 2 , 29 mM HEPES, 2.8 mM MgSO 4 , 1.1 mM K 2 HPO 4 , 6.35 mM glucose, and 1.15 mM sodium ascorbate.
MATERIALS AND METHODS

Animals
Four to 6 mice or 3 or 4 rats were anesthetized with pentobarbital and heparin in saline. The trachea was exposed and cannulated with a stainless steel feeding tube tied in place. The lungs were perfused with gravity-fed buffer A via the right ventricle into the pulmonary artery. The lungs and heart were removed en bloc. The lungs were lavaged with buffer A/ EGTA eight times, and digested at 37°C with warm elastase solution (4.3 U/ml Buffer B, 4 infusions of 5 min each for a total of 20 min). Following digestion, the lobes were cut away from the trachea and heart, pooled and minced to approximately 1-mm 3 pieces. The minced lungs were placed in 8 ml of calf serum in an Erlenmeyer flask, for neutralization of the elastase. The mixture was filtered through cotton gauze, and then 40-m nylon mesh. The resulting solution was layered on top of 8 ml of calf serum in a 50-ml conical centrifuge tube and centrifuged at 90 ϫ g for 20 min. Macrophages were removed by panning, using a plastic petri dish coated with IgG. Following incubation for one h, the dish was rinsed thoroughly with KRH buffer to transfer the cells to a 50-ml conical centrifuge tube, which was centrifuged for 20 min at 90 ϫ g. The supernatant was discarded, and the cell pellet was resuspended in 0.1 M HEPES buffer for use in the styrene metabolism assays.
Cell counting was accomplished with crystal violet and a hemocytometer. All nucleated cells were counted. For enrichment determination, nitro blue tetrazolium (NBT) staining (Devereux and Fouts, 1980) was performed for identification of Clara cells. For identification of type II cell populations, the modified Pap staining procedure was used. Cell viability was determined with trypan blue exclusion.
Elutriation procedure for type II alveolar and Clara cell isolation. When both Clara and type II cells were prepared, the procedure followed was an adaptation of that of Belinsky et al. (1995) . HEPES BS buffer, pH 7.4 (HPBS) was used for perfusion, lavage, and as a large portion of the elutriation buffer. HPBS contained 150 mM NaCl, 6 mM KCl, 3.9 mM KH 2 PO 4 , 0.5 mM glucose, and 25 mM HEPES in sterile water. The elutriation buffer was 2 parts HPBS:1 part F12K (Gibco: Kaighn's modified nutrient mix).
The DNase solution (0.05% in HPBS:F12K) was used to dissociate the clumped material just prior to elutriation. Digestion neutralizing solution was 75 ml HPBS:F12K with 1.0% bovine serum albumin (BSA) and 100 mg soybean trypsin inhibitor. Digestion solution was 0.25% protease in HPBS.
Lungs from male CD-1 mice (usually 10) or Sprague-Dawley rats (usually 5) were surgically removed as previously described and lavaged 5 times with 1 ml (mice) or 5 times with 8 ml (rats) via the tracheal cannula using HPBS. Digestion was accomplished by instilling a 0.25% solution of protease (1 ml for mice and 8 ml for rats) into the lungs. The trachea was tightly clamped, and the lungs were incubated in sterile saline at 37°C for 3 min, followed by room temperature for 7 min. Following digestion, the trachea and heart were removed, and the lungs were minced to approximately 1 mm 3 pieces. The minced lungs were transferred to an Erlenmeyer flask with a vacuum sidearm containing 75 ml cold HPBS:F12K buffer solution containing bovine serum albumin and soybean trypsin inhibitor. This solution was degassed for 1 min and stirred vigorously at 0°C for 10 min to dissociate cell clumps and neutralize the digestion solution. The resulting solution was filtered successively through 2 layers of cheesecloth, followed by 165-m then 40-m nylon mesh. This cell suspension was layered onto 8 ml of calf serum in 50-ml plastic conical centrifuge tubes and centrifuged at 200ϫg for 12 min. The cell pellet was resuspended in 3 ml modified DMEM and incubated with IgG for one hour. Cells were removed using HPBS:F12K (3 times with 3 ml). This suspension was added to 8 ml of HPBS:F12K containing 0.05% DNase I and shaken by hand. Centrifugal elutriation using a Sanderson chamber in a Beckman J-6M/E centrifuge was performed as outlined in Table 1 .
The elutriation fractions, collected in 50 ml sterile conical centrifuge tubes, were then centrifuged at 1000 rpm for 10 min. The cell pellets were resuspended. Fractions 2 and 3 were combined for the Type II enriched fraction. Fraction 5 is the enriched Clara cell fraction. After centrifugation the cell pellets were resuspended in 0.1 M HEPES and used for the styrene metabolism assays.
Styrene metabolism assays. The metabolism of styrene to styrene oxide was determined as previously described (Carlson, 1997a) . When pulmonary and hepatic microsomes were used, the tissues were homogenized in 0.5 M Tris-HCl buffer (pH 7.4) containing 1.15% KCl. Microsomes were prepared by differential centrifugation with the first centrifugation at 9000 ϫ g for 20 min followed by centrifugation of this supernatant at 105,000 ϫ g for 60 min. A minimum of 0.2 to 0.3 mg protein was used per assay. For the isolated lung epithelial cells, approximately 3 ϫ 10 5 to 1.5 ϫ 10 6 cells were used per assay. The microsomes or cells were incubated for 20 min in an incubation mixture containing 2 mM styrene, 5 mM MgCl 2 , 2 mM NADPH, and 1 mM trichloropropene oxide to inhibit epoxide hydrolase in 0.1 M HEPES buffer (pH 7.4), with a total volume of 1.0 ml. Incubations were carried out at 37°C in 25-ml vials with caps with rubber/teflon septa (Pierce, Rockford, IL) in a Dubnoff metabolic shaker. The reaction was terminated after 20 min by the addition of 1 ml cold heptane. After vortexing to extract the styrene and styrene oxide, samples were frozen to remove the aqueous layer. Metabolites in the organic layer were then analyzed using a Chiralpak AS (Chiral Technologies, Exton, PA) guard column (4.6 ϫ 50 mm) and analytical column (4.6 ϫ 250 mm) on a Shimadzu HPLC. The mobile phase was heptane/isopropanol (99:1) at a rate of 1 ml/min. UV detection was at 219 nm. Styrene to styrene oxide metabolism was assayed with and without: (a) diethyldithiocarbamate (DDTC), a CYP2E1 inhibitor at 300 M; (b) ␣-phenyl-␣-propylbenzeneacetic acid 2-[diethylamino]ethyl ester (SKF-525A), a nonspecific inhibitor at 1 mM; (c) 5-phenyl-1-pentyne (5P1P), a CYP2F inhibitor at 5 M; (d) ␣-naphthoflavone (␣-NF), a CYP1A inhibitor at 10 M; and (e) ␣-methylbenzylaminobenzotriazole (MBA), a CYP2B inhibitor at 1 and 10 M.
Statistical analysis. Each assay was carried out 3 or 4 times as indicated in the individual tables. Values for the styrene to styrene oxide metabolism are expressed as mean Ϯ SE. In comparing the inhibitor value with control value, a paired Student t-test was used. The level of significance selected was p Ͻ 0.05.
RESULTS
Initial studies were carried out using microsomal preparations prepared from rat and mouse liver and lung in order to verify the reported species differences in activities and the ratio of (R) to (S) styrene oxide formed. In the rat, more (S)-styrene oxide was formed than (R)-for both liver and lung (Table 2 ). In the mouse, the opposite was true, especially for lung.
In the studies focusing on the identification of the specific cytochromes P450 involved in the metabolism of styrene by Clara cells, these cells were isolated from mice using the procedure of Malkinson et al. (1993) as detailed in Materials and Methods. The percentages of Clara cells were determined using the NBT stain and the Wright stain. With the Wright stain, the distinguishing features of the Clara cell are the nucleus, the lack of cilia, and the absence of granules. The identification of the Clara cell was confirmed with the NBT stain, with the cells staining dark blue considered positive. The cells were also viewed using electron microscopy and the characteristics of the cell type confirmed.
The ratio of R-styrene oxide to S-styrene oxide was determined for each preparation, and means and standard errors were determined. As in the microsomal experiments, the formation of the R-enantiomer by Clara cells was favored over the formation of the S-enantiomer in mice (Table 3 ). In fact, the ratio appeared to be somewhat greater in the isolated cell experiments than in the microsomal experiments. 5P1P was a good inhibitor of the production of both styrene oxide enantiomers, yielding approximately 34% inhibition of activity. In view of the microsomal studies (Carlson et al., 1998) , the results with DDTC are surprising in that they did not show inhibition. A possible reason for this result could be that cellular uptake of DDTC is minimal. SKF525A inhibited the production of both styrene oxide enantiomers, but it is not a specific inhibitor (Table 3 ). In view of this, the effects of additional, more selective inhibitors were determined. ␣-Naphthoflavone, a selective inhibitor of CYP1A, had no inhibitory effect on the metabolism of styrene by isolated Clara cells to either enantiomer of styrene oxide (Table 3) . ␣-Methylbenzylaminobenzotriazole, a selective inhibitor of CYP2B, had a minimal inhibitory effect on styrene metabolism by isolated Clara cells even at the higher concentration of 10 M.
Using the centrifugal elutriation procedure adapted from Belinsky et al. (1995) , as described in Materials and Methods, enrichments of both Clara and type II cells were obtained from mice and rats. In determining the percentages in each experiment, the differential counting techniques used a combination of the Wright, NBT, and Pap stains. In Clara cell-enriched fractions, the identification of Clara cells using the NBT stain was confirmed with low numbers of Pap-positive cells. The NBT stain alone could not be used for differential counting of Clara cells because non-Clara cells do not stain sufficiently to count; therefore, presented Clara cell percentages are conservative estimates. Confirmation of the type II cell was accomplished by electron microscopy. Cell viability was high, at approximately 95% or more. The production of the enantiomers of styrene oxide is presented as pmols/10 6 nucleated cells/min. Since the number of cells used for this calculation was the total number of nucleated cells and was not corrected for the enrichment of any particular cell type, the percentages of enriched cell types are presented in Table 4 .
As expected, the production of the R-enantiomer of styrene oxide was favored over that of the S-enantiomer in both fractions enriched for Clara and for type II cells (Table 4) . Styrene metabolism was greater in the fractions that were enriched for Clara cells than in the fractions enriched for type II alveolar cells. When comparing metabolism of Clara cell-enriched fractions obtained with elutriation with metabolism by Clara cells isolated using the less complex method (Table 3) , the activities are similar.
In studies on isolated rat lung cells, as with the mice, the higher styrene-metabolizing activity within each experiment was associated with the Clara cell-enriched fraction rather than the type II alveolar cell-enriched fraction (Table 4) . However, it is interesting to note that in the preparations enriched for type II cells, the ratio of R-to S-styrene oxide was less than one; approximately 0.5. While this is the opposite of what we have observed in mice, it agrees with our limited studies on rat pulmonary microsomal preparations (Table 2) and what has been reported in the literature (Watabe et al., 1981; Foureman Note. R and S enantiomer values in pmols/10 6 cells/min. Values are mean Ϯ SE for 3 replicates. ND, not determined. al., 1989) . In the preparations enriched for Clara cells, the ratio was very close to one.
DISCUSSION
The lung has been identified as a target site for the acute toxicity of styrene in mice (Gadberry et al., 1996) . Using pulmonary microsomal preparations from mice, the lung has been identified as a location for biotransformation of styrene to styrene oxide (Carlson, 1997a) , considered to be the active metabolite (Bond, 1989) due to its chemical structure. There is limited evidence that styrene is associated with pulmonary tumors in mice but not rats (IARC, 1994) . The basic objective of this study was to determine which types of cells in the lung are responsible for metabolism of styrene. This is an important question, particularly as it may relate the metabolism of styrene to its tumorigenicity in mouse lung. The focus was on the Clara cell and the type II alveolar cell, as these cell types have generally been identified as the most active xenobiotic metabolizing cells in lung.
A useful approach to evaluate relationships between the metabolism of a chemical and its toxicity is the use of specific inhibitors of cytochrome P450 isozymes. Diethyldithiocarbamate, which is a relatively specific inhibitor of CYP2E1 (Ono et al., 1996) , inhibits the formation of both enantiomers of styrene in both liver and lung microsomal preparations (Carlson, 1997b) . 5-Phenyl-1-pentyne inhibits styrene metabolism primarily in the lung (Carlson, 1997b) , indicating the importance of CYP2F2 in this tissue, similar to what has been observed for naphthalene (Chang et al., 1996) . With both DDTC and 5PIP, there is no change in the ratio of the enantiomers formed when compared to the ratio of the controls. Inhibition by SKF-525A occurs in both liver and lung microsomal preparations, but the formation of R-styrene oxide is much less affected than that of the S-enantiomer. This is especially so in the lung where there is no effect on R-styrene oxide formation and nearly complete suppression of S-styrene oxide production (Carlson, 1997b) .
In the isolated Clara cell preparations, the R/S enantiomeric ratio appeared to be even greater than in the microsomal preparations. 5P1P, a CYP2F2 inhibitor, effectively inhibited the production of both styrene oxide enantiomers, yielding a 30 to 50% inhibition of activity. DDTC, a relatively selective inhibitor of CYP2E1, did not show as much inhibition as in the microsomal studies, and the results were not consistent. It is possible that the DDTC may not be taken up readily by the intact cells. Increasing the concentration of DDTC was not feasible since at high concentrations it becomes nonselective. SKF-525A, a non-specific cytochrome P450 isozyme inhibitor, produced inhibition of both styrene oxide enantiomers. In the isolated cell experiments, the enantiomeric ratios were not greatly affected by 5P1P, DDTC, or SKF-525A when compared to their respective controls.
To understand the roles of CYP1A and CYP2B in styrene metabolism better than could be determined from the results obtained with SKF-525A, more selective inhibitors were used. ␣NF, a selective inhibitor of CYP1A, had no inhibitory effect on the metabolism of styrene to either styrene oxide enantiomer by isolated mouse Clara cells. This is not unexpected since Chichester et al. (1991) reported that CYP1A is absent from mouse Clara cells. MBA, used to selectively inhibit CYP2B, exhibited a minimal inhibitory effect on styrene metabolism by isolated mouse Clara cells at the higher concentration of 10 M. Forkert et al. (1989) reported that CYP2E1 is found in the Clara cells. Buckpitt and coworkers Chichester et al., 1994) reported that naphthalene was metabolized to 1R,2S-oxide by CYP2F2 in Clara cells from mouse lung resulting in its bioactivation to a toxic metabolite. DDTC, a CYP2E1 inhibitor, inhibited both styrene oxide enantiomers in microsomal studies, but as noted above, did not show as much inhibition in isolated cells. 5P1P, a CYP2F2 inhibitor, showed a high degree of inhibition in both the pulmonary microsomal studies (Carlson, 1998 ) and the Clara cell preparations. Thus, based on the combined data on inhibitors from the microsomal and isolated cell studies, CYP2E1 and CYP2F2 are believed to be the principal cytochromes P450 involved in the pulmonary metabolism of styrene (Carlson, 1997a) .
Upon examining the results from the isolated cell studies with separate fractions enriched for type II alveolar cells and Clara cells obtained from mouse lung, important conclusions can be drawn. One is that the production of the R-enantiomer remains dominant over the S-enantiomer in both Clara and type II alveolar cell preparations. The R-enantiomer of styrene oxide is more genotoxic (Pagano et al., 1982; Sinsheimer et al., 1993) , and this finding could be related to the increased tumorigenic effects of styrene in mouse lung when compared to the effect of styrene in rat lung. Another conclusion to be drawn is that styrene metabolism is several-fold greater in fractions enriched for Clara cells than in fractions enriched for type II cells. When the percentage enrichments for each fraction are considered, and the activities for the two fractions (Table 4) are solved as simultaneous equations, the values obtained for the R-styrene oxide are 152 pmols/10 6 Clara cells/min and -25 pmols/10 6 type II cells/min. Similarly, for the S-styrene oxide the values are 41.5 pmols/10 6 Clara cells/ min and -1.9 pmols/10 6 type II cells/min. These data then indicate that the type II cells have essentially no styrene metabolizing activity.
In isolated cell studies with the rat, there are some important similarities and differences to note. The ratio of R/S styrene oxides formed is somewhere between 0.5 and 1.0, much less than that observed in mice. This agrees with our limited studies on rat microsomal preparations (Table 2) and what has been reported in the literature (Foureman et al., 1989; Watabe et al., 1981) . However, as in mice, the higher styrene metabolizing activity within each experiment is associated with the fractions enriched for Clara cells rather than the fractions enriched for type II alveolar cells. Using the data from Table 4 and solving as simultaneous equations, gives the activity for the formation of the R-styrene oxide as 30.1 pmols/10 6 Clara cells/min and -0.4 pmols/10 6 type II cells/min and for the S-styrene oxide as 29 pmols/10 6 Clara cells/min and 10 pmols/10 6 type II cells/min. This again shows that the activity, although several-fold lower in the rat isolated cells than in the mouse isolated cells, is primarily, if not exclusively, associated with the Clara cells.
In summary, in all the isolated Clara cell studies with mice, the R-styrene oxide was preferentially formed over the Sstyrene oxide. Studies on isolated lung cells revealed that the styrene oxide R/S ratio is much smaller in isolated cells from rats than in isolated cells from mice. The reason for the difference is unclear. The data using selected inhibitors indicate that CYP1A plays little or no role in the metabolism of styrene to styrene oxide and that CYP2B makes only a minor contribution in naïve animals. This is in contrast to the greater involvement of CYP2E1 and CYP2F2 (especially in lung) as demonstrated by previous studies using selective inhibitors of these cytochrome P450 isozymes (Carlson, 1997b) . The data from the isolated cell studies are consistent with the microsomal work, with the exception of the DDTC results. Finally, all the oxidative metabolism of styrene appears to occur in the Clara cells of mice with none in the type II cells, in accord with the reported distribution of CYP2E1.
